Jeff Ryckman, Assistant Professor of Radiation Oncology at WVU Medicine Camden Clark Medical Center, shared a post on X by Yakup Ergün, Medical Oncologist at Antalya City Hospital, adding:
“Wow, fascinating results, especially considering neoadjuvant Osimertinib is associated with ~2% pCR (n=1/52) according to two prospective single-arm phase II studies!
Congratulations to the authors!”
Quoting Yakup Ergün’s post, about a paper by Dongliang Bian et al. published in Nature Communications:
“Neoadjuvant Aumolertinib for unresectable stage III EGFR-mutant NSCLC.
51 patients
ORR – 70.6% (Beat the 70% goal)
23 patients (45.1%) became operable! R0: 100%, MPR: 21.7%, pCR: 13%
1-yr EFS – 88.2%,
2-yr EFS – 58.8%
G3/4 AE: 9.8%, no G5.”
Authors: Dongliang Bian, Shuyu Ji, Yue Liu, Zhida Huang, Lei Jiang, Chunyan Wu, Deping Zhao, Liang Duan, Gening Jiang, Peng Zhang et al.
More posts featuring Jeff Ryckman and Yakup Ergün.
